Enhancement of a nociceptive reaction by opioid antagonists in mice

British Journal of Pharmacology
J J Jacob, K Ramabadran

Abstract

1. The opioid antagonists, naloxone, GPA 2163, levallorphan and Mr-2266 reduced the latency of the jumping reaction of mice in the hot plate test. The (+)-isomers of levallorphan and Mr-2266 which are devoid of antagonistic activity did not increase this latency. 2. In the same nociceptive reaction test, the enhancing effect of naloxone progressed in a dose-range similar to that required for the antagonism by naloxone of the depressive action of morphine. 3. The facilitatory effect of naloxone was not blocked by the previous administration of morphine or etorphine but it was prevented by pretreatment with a high dose of buprenorphine. 4. The antagonism by naloxone of morphine and of buprenorphine did not follow the same pattern. 5. The factors which are or may be involved in the efficacy of naloxone in enhancing nociceptive reactions are discussed. 6. The enhancing effect of naloxone may be due to an antagonism of endogenous ligands for the opiate receptor. If so, these ligands would be involved in reaction to but not in perception of nociceptive stimuli which need not be harmful ones.

References

Oct 28, 1976·Nature·A El-SobkyP D Wall
Dec 1, 1976·Life Sciences·H W ElliottG Navarro
Dec 1, 1976·Life Sciences·B Pomeranz, D Chiu
Jun 9, 1977·Nature·J A LordH W Kosterlitz
Mar 1, 1977·Brain Research Bulletin·G G Berntson, J M Walker
Jan 1, 1977·Psychoneuroendocrinology·L Terenius
Mar 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·P Grevert, A Goldstein
Jul 18, 1977·Psychopharmacology·P Grevert, A Goldstein
Aug 1, 1977·British Journal of Pharmacology·A CowanI R Macfarlane
Jan 21, 1977·European Journal of Pharmacology·Y AudigierJ C Schwartz
Oct 1, 1977·European Journal of Pharmacology·C J WoolfR A Myers
Dec 1, 1976·Neuropharmacology·J Goldfarb, J W Hu
Jun 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·A Goldstein, E R Hilgard
Jun 15, 1975·Life Sciences·G W PasternakS H Snyder
Apr 15, 1976·Nature·C H Li, D Chung
Jul 11, 1974·Psychopharmacologia·J J JacobM C Colombel
Mar 1, 1957·British Journal of Pharmacology and Chemotherapy·T J HALEY, W G MCCORMICK
Jul 1, 1940·The Journal of Clinical Investigation·J D HardyH Goodell

❮ Previous
Next ❯

Citations

Sep 1, 1979·Psychopharmacology·R J Rodgers, R M Deacon
Mar 1, 1980·Naunyn-Schmiedeberg's Archives of Pharmacology·E Beubler
Jan 1, 1988·Psychopharmacology·J D GreeleyH Cappell
Dec 8, 2011·Journal of Natural Medicines·Adriana G GuimarãesLucindo J Quintans Júnior
Sep 15, 1979·European Journal of Pharmacology·W R Buckett
May 16, 1980·European Journal of Pharmacology·D MiceliJ Le Magnen
Apr 23, 1982·European Journal of Pharmacology·T L Yaksh, G J Harty
Jun 1, 1993·Neuropharmacology·K Grasing, H Szeto
Oct 1, 1993·Toxicon : Official Journal of the International Society on Toxinology·R GiorgiY Cury
May 1, 1980·Pharmacology, Biochemistry, and Behavior·J Le MagnenM Devos
Sep 1, 1983·Pharmacology, Biochemistry, and Behavior·B A TurnbullR S Feldman
Jan 1, 1994·Pharmacology, Biochemistry, and Behavior·S R Hamann, W R Martin
Jan 1, 1981·Pharmacology & Therapeutics·J J Jacob, K Ramabadran
Aug 1, 1991·Journal of Ethnopharmacology·B B LorenzettiS H Ferreira
Jun 1, 2001·Toxicon : Official Journal of the International Society on Toxinology·P BrigatteY Cury
May 30, 1998·Toxicon : Official Journal of the International Society on Toxinology·G PicoloY Cury
Nov 1, 1979·Behavioral and Neural Biology·R B MessingJ L McGaugh
May 30, 2001·Journal of Ethnopharmacology·T Geetha, P Varalakshmi
Nov 1, 1988·The Journal of Clinical Investigation·J D LevineT J Coderre
Apr 6, 2006·Biological & Pharmaceutical Bulletin·Vanu Ramkumar RamprasathPanchanatham Sachdanandam
Feb 22, 2012·Journal of Natural Medicines·Renan G BritoLucindo J Quintans
Mar 1, 1989·Journal of Pharmacological Methods·K RamabadranM M Puig
Jun 23, 1980·Brain Research·G UrcaJ C Liebeskind
Apr 9, 1984·Brain Research·A W DugganZ Q Zhao
Aug 22, 2006·Peptides·Camila Squarzoni DaleRenata Giorgi
Aug 1, 1981·Journal of Clinical Pharmacology·J J JacobM Campos-Medeiros

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.